CKPT Checkpoint Therapeutics, Inc. revenue, earnings and financials
For the quarter ended March 31, 2025, Checkpoint Therapeutics, Inc. reported revenue of n/a, net income of −$11.2M and diluted EPS of −$0.19; for the fiscal year ended December 2024 revenue was $41.0K, down 60.2% on the year before.
CKPT annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $41.0K, gross profit n/a, operating income −$56.2M, net income −$56.2M (margin -137170.7%), EPS −$1.42
- Fiscal year ended Dec 2023: revenue $103K, gross profit n/a, operating income −$52.1M, net income −$51.8M (margin -50336.9%), EPS −$3.17
- Fiscal year ended Dec 2022: revenue $192K, gross profit n/a, operating income −$58.3M, net income −$62.6M (margin -32616.7%), EPS −$7.09
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$56.7M, net income −$56.7M (margin n/a), EPS −$7.45
CKPT quarterly revenue and earnings
- Quarter ended Mar 31, 2025: revenue n/a, net income −$11.2M, EPS −$0.19
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$28.9M, EPS −$0.68
- Quarter ended Sep 30, 2024: revenue n/a, net income −$9.73M, EPS −$0.23
- Quarter ended Jun 30, 2024: revenue $41.0K (up 32.3% year over year), net income −$6.67M, EPS −$0.18
- Quarter ended Mar 31, 2024: revenue n/a, net income −$10.9M, EPS −$0.33
- Quarter ended Dec 31, 2023 (from the annual report): revenue $6.00K, net income −$19.1M, EPS −$0.94
- Quarter ended Sep 30, 2023: revenue $31.0K (down 35.4% year over year), net income −$5.72M, EPS −$0.29
- Quarter ended Jun 30, 2023: revenue $31.0K (up 72.2% year over year), net income −$16.5M, EPS −$1.05
- Quarter ended Mar 31, 2023: revenue $35.0K, net income −$10.5M, EPS −$0.89
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$21.0M, EPS −$2.29
- Quarter ended Sep 30, 2022: revenue $48.0K, net income −$10.6M, EPS −$1.20
- Quarter ended Jun 30, 2022: revenue $18.0K, net income −$14.1M, EPS −$1.62
- Quarter ended Mar 31, 2022: revenue n/a, net income −$16.8M, EPS −$1.98
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$29.8M, EPS −$7.28
- Quarter ended Sep 30, 2021: revenue n/a, net income −$11.3M, EPS −$0.14
- Quarter ended Jun 30, 2021: revenue n/a, net income −$9.14M, EPS −$0.12
- Quarter ended Mar 31, 2021: revenue n/a, net income −$6.51M, EPS $0.09
CKPT cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$31.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$47.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$57.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$26.3M, share buybacks n/a
CKPT balance sheet
- Mar 31, 2025: cash $33.0M, total assets $34.2M, total liabilities $17.9M, shareholders' equity $16.3M
- Dec 31, 2024: cash $6.60M, total assets $7.47M, total liabilities $20.1M, shareholders' equity −$12.6M
- Sep 30, 2024: cash $4.70M, total assets $5.18M, total liabilities $17.8M, shareholders' equity −$12.6M
- Jun 30, 2024: cash $4.95M, total assets $5.67M, total liabilities $21.4M, shareholders' equity −$15.7M
- Mar 31, 2024: cash $11.2M, total assets $12.0M, total liabilities $22.2M, shareholders' equity −$10.3M
- Dec 31, 2023: cash $4.93M, total assets $5.38M, total liabilities $18.4M, shareholders' equity −$13.0M
- Sep 30, 2023: cash $1.77M, total assets $2.22M, total liabilities $21.3M, shareholders' equity −$19.0M
- Jun 30, 2023: cash $7.42M, total assets $8.34M, total liabilities $31.6M, shareholders' equity −$23.3M
What is CKPT's revenue?
Checkpoint Therapeutics, Inc. reported $41.0K of revenue for the fiscal year ended December 2024.
Is CKPT profitable?
No. Checkpoint Therapeutics, Inc. lost $56.5M over the last four quarters.
What is CKPT's EPS?
Diluted earnings per share over the last four quarters were −$1.28; −$0.19 in the latest quarter.